The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of Type 2 diabetes mellitus

Diabetic Medicine

Volumn 32, Issue 7, 2015, Pages 890-898

  Charokopou, M ^a   McEwan, P ^b,c   Lister, S ^d   Callan, L ^e   Bergenheim, Klas ^f   Tolley, K ^g   Postema, R ^d   Townsend, R ^e   Roudaut, M ^d  

^a PHARMERIT INTERNATIONAL   (Netherlands)

^b SWANSEA UNIVERSITY   (United Kingdom)

^c HEALTH ECONOMICS AND OUTCOMES RESEARCH LTD   (United Kingdom)

^d BRISTOL MYERS SQUIBB   (United States)

^e ASTRAZENECA   (United Kingdom)

^f ASTRAZENECA R AND D   (Sweden)

^g Tolley Health Economics   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DAPAGLIFLOZIN; GLICLAZIDE; INSULIN; METFORMIN; SULFONYLUREA; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSIDE; SODIUM GLUCOSE COTRANSPORTER; SULFONYLUREA DERIVATIVE;

ADD ON THERAPY; ADULT; ARTICLE; BLINDNESS; CEREBROVASCULAR ACCIDENT; CLINICAL ASSESSMENT; CONFIDENCE INTERVAL; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIABETIC ANGIOPATHY; DIABETIC MICROANGIOPATHY; DIABETIC PATIENT; DISEASE COURSE; DRUG COST; DRUG EFFICACY; DRUG SAFETY; END STAGE RENAL DISEASE; FEMALE; GENITAL TRACT INFECTION; GLYCEMIC CONTROL; HEART INFARCTION; HUMAN; HYPOGLYCEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SENSITIVITY ANALYSIS; UNCERTAINTY; UNITED KINGDOM; URINARY TRACT INFECTION; ADVERSE EFFECTS; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; COMPLICATION; COST BENEFIT ANALYSIS; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DRUG COMBINATION; DRUG EFFECTS; DRUG RESISTANCE; ECONOMICS; HEALTH CARE COST; HYPERGLYCEMIA; METABOLISM; OVERWEIGHT; RISK; WEIGHT REDUCTION;

BENZHYDRYL COMPOUNDS; COHORT STUDIES; COST-BENEFIT ANALYSIS; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; GLUCOSIDES; GREAT BRITAIN; HEALTH CARE COSTS; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; OVERWEIGHT; QUALITY-ADJUSTED LIFE YEARS; RISK; SODIUM-GLUCOSE TRANSPORT PROTEINS; SULFONYLUREA COMPOUNDS; WEIGHT LOSS;

EID: 84936985361     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12772     Document Type: Article

References (43)

1. Coyle D, Lee KM, O'Brien BJ. The role of models within economic analysis: focus on type 2 diabetes mellitus. PharmacoEconomics 2002; 20(Suppl 1): 11-19.
2. Haddix AC, Teutsch SM, Corso PS. Prevention Effectiveness: a guide to decision analysis and economic evaluation: Oxford: Oxford University Press, 2003.
3. The National Collaborating Centre for Chronic Conditions. Type 2 Diabetes: national clinical guideline for management in primary and secondary care (update). Royal College of Physicians, 2008. Available at http://www.nice.org.uk/guidance/cg66/resources/cg66-type-2-diabetes-full-guideline2 Last accessed 1 November 2014.
4. House of Commons Committee of Public Accounts. The management of adult diabetes services in the NHS (October 2012). Available at http://www.publications.parliament.uk/pa/cm201213/cmselect/cmpubacc/289/289.pdf Last accessed 3 April 2015.
5. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-1379.
6. National Diabetes Audit. National Diabetes Audit Executive Summary. Available at http://www.hscic.gov.uk/catalogue/PUB12421/nati-diab-audi-11-12-care-proc-rep.pdf Last accessed 1 November 2014.
7. National Collaborating Centre for Chronic Conditions, Centre for Clinical Practice at NICE. NICE Clinical Guideline 87. Type 2 Diabetes: the management of type 2 diabetes. London: National Institute for Health and Clinical Excellence, 2009.
8. Phung OJ, Scholle JM, Talwar M, Coleman CI. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA 2010; 303: 1410-1418.
9. List JF, Whaley JM. Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans. Kidney Int Suppl 2011; 120: S20-S27.
10. Nauck MA, Del Prato S, Meier JJ, Durán-García S, Rohwedder K, Elze M et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, activecontrolled noninferiority trial. Diabetes Care 2011; 34: 2015-2022.
11. Charokopou M, McEwan P, Lister S, Callan L, Bergenheim K, Tolley K et al. The cost-effectiveness of dapagliflozin (Forxiga) versus a DPP-4 inhibitor in the treatment of type 2 diabetes mellitus (T2DM) in England and Wales. Value Health 2013; 16: A440.
12. van Haalen HG, Pompen M, Bergenheim K, McEwan P, Townsend R, Roudaut M. Cost effectiveness of adding dapagliflozin to insulin for the treatment of type 2 diabetes mellitus in the Netherlands. Clin Drug Invest 2014; 34: 135-146.
13. McEwan P, Evans M, Bergenheim K. A population model evaluating the costs and benefits associated with different oral treatment strategies in people with type 2 diabetes. Diabetes Obes Metab 2010; 12: 623-630.
14. The Mount Hood 4 Modeling Group. Computer modeling of diabetes and its complications. Diabetes Care 2007; 30: 1638-1646.
15. Clarke P, Gray A, Briggs A, Farmer AJ, Fenn P, Stevens AJ et al. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia 2004; 47: 1747-1759.
16. Office of National Statistics. UK Life Expectancy Tables. Available at www.ons.gov.uk/ons/taxonomy/index.html?nscl=Life+Tables Last accessed 1 November 2014.
17. Barlow J, Krassas G. Improving management of type 2 diabetes: findings of the Type2Care clinical audit. Aust Fam Physician 2013; 2: 57.
18. Del Prato S, Nauck M, Rohwedder K et al., editors. Long-term efficacy and safety of dapagliflozin vs add-on glipizide in patients with type 2 diabetes inadequately controlled with metformin:2 year results. Presented at the 47th Annual Meeting of the European Association for the Study of Diabetes, 2011.
19. Clarke P, Gray A, Legood R, Briggs A, Holman R. The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65). Diabet Med 2003; 20: 442-450.
20. National Health Service (NHS) UK. England and Wales Drug Tariff (Feb 2012). Available at www.nhsbsa.nhs.uk/prescriptions Last accessed 1 November 2014.
21. Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 2002; 22: 340-349.
22. Currie C, McEwan P, Peters J, Patel TC, Dixon S. The routine collation of health outcomes data from hospital treated subjects in the Health Outcomes Data Repository (HODaR): descriptive analysis from the first 20,000 subjects. Value Health 2005; 8: 581-590.
23. Barry HC, Ebell MH, Hickner J. Evaluation of suspected urinary tract infection in ambulatory women: a cost-utility analysis of office-based strategies. J Fam Pract 1997; 44: 49-60.
24. Lane S, Levy AR, Sambrook J, Mukherjee J, Leahy M, Tildesley H. PDB72 The impact on utilities of weight loss and weight gain among canadian patients with type 2 diabetes. Value Health 2012; 15(4): A183.
25. Currie CJ, Morgan CL, Poole CD, Sharplin P, Lammert M, McEwan P. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin 2006; 22: 1523-1534.
26. Erhardt W, Bergenheim K, Duprat-Lomon I, McEwan P. Cost effectiveness of saxagliptin and metformin versus sulfonylurea and metformin in the treatment of type 2 diabetes mellitus in Germany. Clin Drug Invest 2012; 32: 189-202.
27. Granstrom O, Bergenheim K, McEwan P, Sennfält K, Henriksson M. Cost-effectiveness of saxagliptin (Onglyza®) in type 2 diabetes in Sweden. Primary Care Diabetes 2012; 6: 127-136.
28. National Institute for Health and Care Excellence. Guide to the Methods of Technology Appraisal. 2013.
29. Fox KM, Gerber RA, Bolinder B, Chen J, Kumar S. Prevalence of inadequate glycemic control among patients with type 2 diabetes in the United Kingdom general practice research database: a series of retrospective analyses of data from 1998 through 2002. Clin Ther 2006; 28: 388-395.
30. Calvert MJ, McManus RJ, Freemantle N. Management of type 2 diabetes with multiple oral hypoglycaemic agents or insulin in primary care: retrospective cohort study. Br J Gen Pract 2007; 57 (539): 455-460.
31. Bagust A. Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Econ 2005; 14: 217-230.
32. Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B et al. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. Health Technol Assess 2010; 14: 1-248.
33. Cummins E, Scott N, Rothnie K, Waugh N, Fraser C, Philip S et al. Evidence Review Group report; Dapagliflozin for the treatment of type 2 diabetes. 2013. Available at http://www.nice.org.uk/guidance/ta288/documents/diabetes-type-2-dapagliflozin-evidence-reviewgroup-report3 Last accessed 3 April 2015.
34. Palmer AJ. Computer modeling of diabetes and its complications: a report on the fifth Mount Hood Challenge meeting. Value Health 2013; 16: 670-685.
35. Charokopou M, Sabater F, Townsend R, Roudaut M, Verheggen BG. Overview of health economic models in type 2 diabetes mellitus: a systematic literature review. Value Health 2013; 16: A591.
36. Scottish Medicines Consortium. Dapagliflozin for the Treatment of Type 2 Diabetes. 2012. Available at https://www.scottishmedicines.org.uk/SMC_Advice/Advice/799_12_dapagliflozin_Forxiga/dapagliflozin_Forxiga Last accessed 3 April 2015.
37. Yang F, Ye J, Pomerantz K, Stewart M. Potential modification of the UKPDS risk engine and evaluation of macrovascular event rates in controlled clinical trials. Diabetes Metab Syndr Obes 2013; 6: 247-256.
38. Del Prato A, Nauck M, Duran-Garcia S, Rohwedder K, Theuerkauf A, Langkilde AM et al. Durability of dapagliflozin vs glipizide as add-on therapies in T2DM indadquately controlled on metformin: 4 year data. Presented at the 73rd American Diabetes Association Meeting, Chicago IL, June 21-25 2013.
39. Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a metaanalysis. Diabetes Res Clin Pract 2008; 81: 184-189.
40. Montañana CF, Herrero CH, Fernández MR. Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients-The PREDICTIVE™ BMI clinical trial. Diabet Med 2008; 25: 916-923.
41. Baboolal K, McEwan P, Sondhi S, Spiewanowski P, Wechowski J, Wilson K. The cost of renal dialysis in a UK setting-a multicentre study. Nephrol Dial Transplant 2008; 23: 1982-1989.
42. Hammer M, Lammert M, Mejias SM, Kern W, Frier BW. Costs of managing severe hypoglycaemia in three European countries. J Med Econ 2009; 12: 281-290.
43. Personal Social Services Research Unit. Unit Costs of Health and Social Care. Available at http://www.pssru.ac.uk/project-pages/unit-costs/2012/index.php Last accessed 1 November 2014.